Company intelligence / Profile preview

Synaptikon

Berlin, Berlin, Germany

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Synaptikon is a Berlin-based digital health company founded in 2011 that develops and commercializes evidence-based cognitive training products. Its best-known healthcare offering is NeuroNation MED, a digital therapeutic-style brain training platform focused on the prevention and treatment support of mild to moderate cognitive impairment. The company combines neuroscience, clinical validation, and app-based engagement methods to deliver personalized cognitive exercises at scale. Synaptikon appears to operate as a commercial-stage digital health company rather than a traditional drug developer, with no evidence of a conventional biopharma pipeline involving molecular therapeutics.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Synaptikon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptikon.

Explore the full profile